C4 Therapeutics, Inc. — Director's Dealing 2022

May 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2022-05-25

Reporting Person: Schick Kelly (Chief People Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-25	Common Stock	M	3750	—	Acquired	3750	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-25	Performance Restricted Stock Units	$	M	3750	Disposed	2025-02-28	Common Stock (3750)	Direct

Footnotes

F1: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.